OverviewSuggest Edit

Anixa Biosciences (formerly known as ITUS Corporation) is a biotechnology company providing diagnostic and therapeutic solutions for the early detection of tumor-based cancers. It develops a diagnostic platform called Cchek, a series of non-invasive blood tests which can be used for conventional screening, confirmatory testing, and treatment and recurrence monitoring. The Company also develops chimeric antigen receptor T-cell (CAR-T) based immunotherapy drugs which genetically engineer a patient’s own immune cells to fight cancer. 
TypePublic
Founded1982
HQSan Jose, CA, US
Websiteanixa.com

Latest Updates

Employees (est.) (Oct 2019)7
Revenue (FY, 2019)$250 K(-77%)
Share Price (Jan 2021)$3.9 (+2%)
Cybersecurity ratingAMore

Key People/Management at Anixa Biosciences

Amit Kumar

Amit Kumar

Chairman, President & Chief Executive Officer
Michael Catelani

Michael Catelani

Chief Operating Officer and Chief Financial Officer
Arnold Baskies

Arnold Baskies

Director
Lew Titterton

Lew Titterton

Lead Independent Director
David Cavalier

David Cavalier

Director
John Monahan

John Monahan

Director
Show more

Anixa Biosciences Office Locations

Anixa Biosciences has an office in San Jose
San Jose, CA, US (HQ)
3150 Almaden Expy #250
Show all (1)

Anixa Biosciences Financials and Metrics

Anixa Biosciences Revenue

Anixa Biosciences's revenue was reported to be $250 k in FY, 2019
USD

Net income (FY, 2020)

(10.1m)

EBIT (FY, 2020)

(10.0m)

Market capitalization (13-Jan-2021)

100.9m

Closing stock price (13-Jan-2021)

3.9

Cash (31-Oct-2020)

6.4m

EV

94.6m
Anixa Biosciences's current market capitalization is $100.9 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

1.0m947.1k388.9k3.7m9.3m300.0k362.5k1.1m250.0k

Revenue growth, %

152%

Cost of goods sold

34.1k3.9k

Gross profit

969.1k943.2k
Quarterly
USDQ3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

450.4k449.2k248.1k249.5k2.1k1.2m9.1m25.0k95.0k100.0k362.5k750.0k362.5k

Cost of goods sold

3.6k737.0497.0714.027.1k

Gross profit

446.7k448.5k247.6k248.8k(24.9k)

Gross profit Margin, %

99%100%100%100%(1171%)
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

774.0k339.7k898.2k3.4m4.4m2.5m3.3m3.1m3.5m6.4m

Accounts Receivable

7.0k175.0k400.0k66.5k2.2k

Prepaid Expenses

97.2k82.3k160.6k60.6k126.5k162.1k174.6k482.5k185.0k309.3k

Current Assets

3.1m922.0k1.2m6.3m6.9m3.4m7.0m5.5m6.1m9.4m
Quarterly
USDQ3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

551.4k463.0k130.7k101.5k1.7m1.3m982.0k776.1k617.7k3.7m7.8m6.1m5.2m4.0m2.6m2.0m1.4m2.9m1.8m2.8m4.2m2.6m4.2m3.8m4.4m2.8m2.9m5.9m

Accounts Receivable

828.4k133.3k45.0k221.0k797.0k1.1k22.3k32.3k6.0k

Prepaid Expenses

61.0k97.2k107.5k93.3k67.0k52.1k47.3k141.3k134.2k100.6k66.5k42.5k193.6k55.8k39.0k56.4k68.6k64.6k140.3k278.5k298.2k378.5k333.7k124.3k129.6k154.5k116.3k189.8k

Inventories

33.4k
USDQ3, 2011

Financial Leverage

4.5 x
Show all financial metrics

Anixa Biosciences Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Anixa Biosciences Online and Social Media Presence

Embed Graph

Anixa Biosciences News and Updates

Anixa Biosciences Announces Presentation at AI and Big Data in Cancer Conference

SAN JOSE, Calif., March 2, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced that data related to Anixa's recently launched Cchek™ Prostate Cancer Confirmation...

Anixa Biosciences to Present at Biotech Showcase 2020

SAN JOSE, Calif., Dec. 23, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced that its chief executive officer, Dr. Amit Kumar, will present at the Biotech...

Anixa Biosciences Announces Commercial Launch of Cchek™ Prostate Cancer Confirmatory Test

SAN JOSE, Calif., Dec. 16, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced the commercial launch of its Cchek™ Prostate Cancer Confirmation test (Cchek™ PCC),...

Anixa Biosciences to Host Conference Call to Discuss Plans for 2020

SAN JOSE, Calif., Dec. 13, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced that it will hold a conference call on December 17, 2019 at 1:30 p.m. Pacific / 4:30...

Anixa Biosciences Provides Update on CAR-T Program

SAN JOSE, Calif., Dec. 13, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced an update regarding the chimeric antigen receptor T-cell (CAR-T) technology it is...

Anixa Biosciences Announces Collaboration with Urology Centers of Alabama on Cchek™ Prostate Cancer Study

SAN JOSE, Calif., Nov. 22, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced a collaboration with Urology Centers of Alabama (UCA) in the Cchek™ early prostate...
Show more

Anixa Biosciences Blogs

Anixa Biosciences CAR-T Cancer Therapy Patent Receives Notice of Allowance

SAN JOSE, Calif., Jan. 24, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for the first patent covering Anixa …

Anixa Biosciences Announces Completion of Pre-Sub Meeting with FDA for its Cchek™ Cancer Diagnostic Test

SAN JOSE, Calif., Dec. 19, 2018 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that it completed a Pre-Submission (Pre-Sub) meeting with the US FDA on December 17, 2018.  …

Anixa Biosciences Presents Positive Data on its Liquid Biopsy for Early Detection of Breast Cancer at AACR Conference

SAN JOSE, Calif., Dec. 3, 2018 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, presented the latest data from its ongoing study focusing on early detection of breast cancer, utilizing Cchek™, its artificial …

Anixa Biosciences To Present Cchek™ Breast Cancer Data at AACR Special Conference on Tumor Immunology and Immunotherapy

SAN JOSE, Calif., Nov. 15, 2018 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that it will present data from its ongoing studies in breast cancer utilizing Cchek™, Anixa's artificial intell…

Anixa Biosciences Presents Positive Data from its Artificial Intelligence Powered Liquid Biopsy for Prostate Cancer at SITC Conference

SAN JOSE, Calif., Nov. 12, 2018 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that its two presentations at the 33rd Annual Meeting of The Society for Immunotherapy of Cancer (SITC) are now…

Anixa Biosciences Announces Scheduling of Pre-Sub Meeting with FDA for its Cchek™ Cancer Diagnostic Test

SAN JOSE, Calif., Oct. 24, 2018 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that a Pre-Submission (Pre-Sub) meeting with the US FDA has been scheduled on Monday, December 17, 2018.  The m…
Show more

Anixa Biosciences Frequently Asked Questions

  • When was Anixa Biosciences founded?

    Anixa Biosciences was founded in 1982.

  • Who are Anixa Biosciences key executives?

    Anixa Biosciences's key executives are Amit Kumar, Michael Catelani and Arnold Baskies.

  • How many employees does Anixa Biosciences have?

    Anixa Biosciences has 7 employees.

  • Who are Anixa Biosciences competitors?

    Competitors of Anixa Biosciences include Grail, Chronix Biomedical and Immunovia.

  • Where is Anixa Biosciences headquarters?

    Anixa Biosciences headquarters is located at 3150 Almaden Expy #250, San Jose.

  • Where are Anixa Biosciences offices?

    Anixa Biosciences has an office in San Jose.

  • How many offices does Anixa Biosciences have?

    Anixa Biosciences has 1 office.